Aperio Group LLC Has $2.62 Million Position in Bioverativ Inc (BIVV)

Aperio Group LLC reduced its holdings in Bioverativ Inc (NASDAQ:BIVV) by 9.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 48,646 shares of the biotechnology company’s stock after selling 4,798 shares during the period. Aperio Group LLC’s holdings in Bioverativ were worth $2,623,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BIVV. BP PLC bought a new stake in shares of Bioverativ during the 3rd quarter worth about $799,000. Whittier Trust Co. of Nevada Inc. bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $293,000. Catalyst Capital Advisors LLC bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $5,707,000. American Century Companies Inc. bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $48,168,000. Finally, Stifel Financial Corp bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $3,576,000. Hedge funds and other institutional investors own 97.18% of the company’s stock.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Monday, January 1st. Jefferies Group upped their price target on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a research report on Thursday, January 18th. Morgan Stanley upgraded shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, January 23rd. Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the company a “hold” rating in a research note on Monday, November 20th. Finally, Argus reaffirmed a “hold” rating on shares of Bioverativ in a research note on Wednesday, January 24th. Twelve equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $63.83.

Bioverativ Inc (NASDAQ BIVV) remained flat at $$104.98 on Wednesday. The stock has a market capitalization of $11,360.00 and a PE ratio of 38.31. Bioverativ Inc has a twelve month low of $48.14 and a twelve month high of $105.01.

Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. The company had revenue of $328.70 million during the quarter, compared to analyst estimates of $325.89 million. equities research analysts expect that Bioverativ Inc will post 3.82 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by Equities Focus and is owned by of Equities Focus. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.equitiesfocus.com/2018/03/14/aperio-group-llc-sells-4798-shares-of-bioverativ-inc-bivv.html.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply